In the KIT D816mut/CBFneg SM-AML cohort, 16 patients received non-intensive therapy only, with a median OS of 2.7 months (95% CI [1.5–3.9]), while all 17 KIT D816mut/CBFneg AMLdatabases patients received intensive chemotherapy. The gene discussed is KIT; the disease is acute myeloid leukemia.